COIOSDeep risk insights through multi-disciplinary research across the globe
The Pennysylvania State Capitol signage
Item new Preprint · not peer-reviewed Added

Medicaid GLP-1 weight-management dispensing fell 85% after four states ended coverage

Weight-management GLP-1 prescriptions in four Medicaid programmes fell 85% in one quarter, with no rise in diabetes-labelled dispensing.

California, New Hampshire, Pennsylvania and South Carolina ended Medicaid weight-management GLP-1 coverage on 1 January 2026. The authors used State Drug Utilization Data from 2024 Q1 to 2026 Q1, classifying products by FDA-approved indication. In the withdrawing states, prescriptions fell 85% between 2025 Q3 and 2026 Q1, from 1.06 to 0.16 per 100 enrollee-months. Six states that kept coverage went from 0.90 to 0.82 (difference-in-differences -0.67; 95% CI -1.21 to -0.18). GLP-1s labelled for other indications did not rise against 33 never-covering states (-0.03; 95% CI -0.29 to 0.23). The analysis covers only the first quarter after coverage ended.

Why it is interesting: These four states held 60.5% of national Medicaid weight-management GLP-1 prescriptions before coverage ended. Within one quarter their dispensing fell 85%, and dispensing of diabetes-labelled products did not rise.

Source
medRxiv, 17 November 2026
Paper
Changes in Medicaid GLP-1 Prescription Dispensing After 4 States Ended Weight-Management Coverage
Authors
Lo W, Conti RM, Nguyen T, Gupta S, Wing C, Simon K
DOI
10.64898/2026.11.15.26368150
Type
Preprint
Design
Difference-in-differences of state drug utilisation data, 2024 Q1–2026 Q1, 4 withdrawing vs 6 continuing and 33 never-covering states; 1.09m weight-management prescriptions in 2025 Q4
Verdict
New finding
Driver
Health systems and access
Driver
Obesity, diabetes and GLP-1

Other drivers in Data, models and systems